RR MedSciences has developed a breakthrough small molecule that uniquely tunes the inflammatory response and arrests free-radical damage, protecting DNA, promoting cellular repair, and modulating pain.
Dedicated to driving medical innovation and changing lives, RR MedSciences is forging a new path in the treatment of pain and inflammatory conditions and applying smart science to health advancement.
Our core technology RM191A is a small molecule immunomodulator and SOD mimetic. It significantly improves healing by mimicking and outperforming an innate feature of the immune system and addressing ROS and RNS activity.
RR MedSciences development pipeline includes novel therapeutics for pain relief, free radical, and inflammatory driven conditions and diseases. Data from pre-clinical studies demonstrates our technology's activities and multitude of possible indications.
Read our peer-reviewed paper on RM191A, published in Redox Biology, Skin protective and regenerative effects of RM191A, a novel superoxide dismutase mimetic, Jan 2021.
Delivery and Formulations
RR MedSciences has advanced viable transdermal formulations featuring RM191A that are proven to be stable and effective for therapeutic delivery. The nature of the compound lends itself to multiple delivery systems.
Clinical Trial Stage
RM191A has now completed a Phase 2a Clinical Trial for Neuropathic Pain in Sydney Australia. (CT Ref No: HREC/16/HAWKE/483). Results will be announced and published soon.
Our patented platform technology has an impressive array of applications.
RM191A works to reduce pain through multiple pathways, by reducing inflammatory and immune activation, and quenching free radicals which activate pain signalling pathways. RM191A is in clinical stage testing as a topical drug to treat chronic, severe, refractory neuropathic pain. The phase 2 clinical trial was conducted at the Pain Management Research Centre at Royal North Shore Hospital, Sydney Australia (CT Ref No: HREC/16/HAWKE/483; ACTRN12617000206325). The results of the trial will be announced at the International Association for the Study of Pain World Congress in September 2022.
Chronic inflammation drives a multitude of disease conditions. RM191A acts at the start of inflammatory processes, inhibiting activation of the inflammatory cascade, down-regulating pro-inflammatory signalling pathways, suppressing ROS/RNS, and beneficially modulating immune cell activation. Topical application of RM191A has been shown to reduce inflammation by 75%.
Free radical neutralisation
RM191A is a unique SOD mimetic, neutralising radical oxygen and nitrogen species in the body. These free radicals cause damage to cellular function and trigger inflammatory and immune processes as well as pain. While the body has an innate system for dealing with free radical damage (SOD), RM191A outperforms innate SOD by around 20x.
Protects against UV radiation damage
Ultraviolet radiation causes damage to skin cells and DNA. RM191A has been shown not only to protect the DNA in the dermis and epidermis during UV exposure, but also enhances skin repair following UV exposure.
RM191A accelerates wound healing and skin regeneration. In skin injury tests, RM191A in gel reduced wound healing by half. Cutting healing time from 23 days, to 10-12 days. It also improves collagen formation following injury by more than 100x.
One major factor in ageing is skin damage. Skin damage occurs via several processes. RM191A has been shown to reduce age-associated oxidative stress in skin, improve collagen production by more than 100x, and reduce age-related immune cell (mast cell) infiltration by 70%.